Agile Therapeutics, Inc. (AGRX)
Chart Events
Performance Outlook
| Previous Close | 1.3900 |
| Open | 1.3900 |
| Bid | 1.2700 x 1400 |
| Ask | 1.3200 x 800 |
| Day's Range | 1.2500 - 1.4200 |
| 52 Week Range | 1.2200 - 67.6000 |
| Volume | |
| Avg. Volume | 378,971 |
| Market Cap | 156.601M |
| Beta (5Y Monthly) | 1.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Agile Therapeutics to Present at The H.C. Wainwright Global Investment Conference
PRINCETON, N.J., May 17, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, announced that Al Altomari, Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference taking place May 23-May 26, 2022 in Miami, FL. Details on the Company presentation are as follows: Event:H.C. Wainwright Global Investment ConferenceDate:Tuesday, May 24, 2022Time:10:00-10:30 am ET The H.C. Wainwright Global Investment Conference w
- GlobeNewswire
Agile Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
Twirla Experienced Another Quarter of Double-Digit Demand Growth in First Quarter 2022 Twirla Business Plan Progressing Company Anticipates Future 2022 Quarterly Operating Expenses to be Lower Management to Host Conference Call Today, Thursday, May 12, 2022 at 4:30 p.m. ET PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2022 and provided a corporate updat
- GlobeNewswire
Agile Therapeutics Announces Findings of First-Year Post-Marketing Pharmacovigilance in ACOG Poster Presentation
PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today publicly released the findings of its first year of post-marketing pharmacovigilance safety surveillance for Twirla® (levonorgestrel and ethinyl estradiol) transdermal system (LNG/EE TDS). The contraceptive transdermal delivery system was approved by the U.S. Food and Drug Administration (“FDA”) in February 2020 as a method of contraception for use in women of reproducti
